Bio Green Med Solution, Inc. quarterly report, Q3 FY2022

Business context and reporting period

The supplied filing is Cyclacel Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2022—not a filing for Bio Green Med Solution, Inc. Cyclacel is a clinical-stage oncology biotech focused on fadraciclib and CYC140; it reported no revenue. Figures below are in U.S. dollars and, unless noted, millions.

Financial performance and liquidity

Gross margin is not applicable because the company reported no revenue. Other income for the first nine months was $1.896 million, including $1.294 million of royalties under an asset purchase agreement, foreign-exchange gains of $0.514 million, and $0.088 million of interest income. Income tax benefit, primarily U.K. R&D tax credits, was $3.136 million.

At September 30, cash and cash equivalents were $23.706 million, down from $36.559 million at December 31, 2021. Working capital was $23.562 million. Total liabilities were $4.460 million, including $0.107 million of lease liabilities; the filing reports no material debt. Total assets were $31.021 million. Nine-month operating cash use was $15.658 million, investing cash use $0.007 million, and financing cash provided $2.956 million. Cash runway was estimated to fund planned operations through the end of 2023.

Material changes versus the prior comparable period

• Nine-month R&D expense rose $2.688 million, or 25%, largely as clinical trial spending increased for fadraciclib and CYC140. Q3 R&D rose 5% year over year.
• Nine-month G&A declined 5%, while Q3 G&A rose 15%, partly due to approximately $0.4 million in costs associated with the ATM sales agreement.
• Nine-month operating cash use increased by $1.667 million year over year. Financing cash inflows fell from $20.850 million to $2.956 million, as the prior-year period included a public offering and warrant exercises.
• Common shares outstanding increased from 9,993,135 at year-end 2021 to 12,539,189 at September 30, 2022. The company also reclassified 3,117,100 shares and $4.494 million of proceeds as redeemable common stock outside equity because of potential rescission rights.

Outlook, commentary, risks and unusual items

Management expected 2022 R&D expense to increase from 2021 as clinical programs progressed, and G&A expense to decrease slightly. The company expects no revenue for the foreseeable future and does not have sufficient funds to complete development and commercialization of its candidates. It expects to need additional capital beyond 2023; funding may not be available on acceptable terms or at all, potentially requiring delays, reductions, cancellations, or earlier partnering of programs.

Clinical updates: fadraciclib studies were enrolling at dose escalation levels six and four, respectively, in solid tumors/lymphomas and hematological malignancies. The CYC140 Phase 1/2 study began dosing in April 2022. COVID-19-related supply-chain and trial-enrollment disruptions, geopolitical conditions, currency movements, and dependence on R&D tax credits and royalty receipts are cited uncertainties. The company said its disclosure controls were effective and reported no significant changes in internal controls.

A significant securities-law contingency arose after the company discovered its shelf registration statement had expired on June 21, 2022. It had sold shares under the ATM agreement through August 12, 2022; purchasers may have rescission rights, and regulatory penalties or claims are possible. No rescission claims or demands had been reported by September 30. The filing states potential repayment of approximately $4.494 million, excluding interest, if all affected purchasers were entitled to rescission. The ATM agreement was terminated. The filing also says the company intends to terminate its sapacitabine license, with termination expected effective March 23, 2023.

Key facts investors should verify

• Confirm the filing identity: the supplied document is Cyclacel Pharmaceuticals, Inc. (CYCC/CYCCP), not Bio Green Med Solution, Inc.
• Review the ATM sales disclosure and potential rescission exposure. The filing gives 3,117,100 shares in the financial note and risk factor, but the unregistered-sales section says 3,177,100 shares; verify the correct share count.
• Assess cash burn against the stated runway through 2023 and the company’s dependence on future financing.
• Track clinical-trial enrollment, safety, dose escalation, and clinical activity for fadraciclib and CYC140, as well as the planned sapacitabine license termination.
• Check the sustainability and timing of U.K. R&D tax credits and royalty income, which management says it cannot reliably forecast.